0.8420EUR-0.35%Mkt Cap: 232.59M EURP/E: —Last update: 2026-05-14
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II cl…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-3.81
PEG3.08
P/B1.89
P/S32.26
EV/EBITDA-3.56
EV/Revenue16.64
EPS (TTM)-0.26
EPS (Forward)-0.22
Cash Flow & Leverage
FCF Yield-10.80%
FCF Margin-348.38%
Operating CF-37.05M EUR
CapEx (TTM)842.00K EUR
Net Debt/EBITDA3.25
Net Debt-109.80M EUR
Technical
SMA 500.7688 (+9.5%)
SMA 2000.9868 (-14.7%)
Beta0.73
S&P 52W Chg24.23%
Avg Vol (30d)54.95K
Avg Vol (10d)58.55K
Technical Indicators
RSI (14)70.3
MACD0.0114
MACD Signal0.0009
MACD Hist.+0.0105
BB Upper0.8271 EUR
BB Middle0.7710 EUR
BB Lower0.7148 EUR
BB Width14.56%
ATR (14)0.0286 EUR
Vol Ratio (20d)0.88x
52W Range
0.530032% of range1.500
52W High1.500 EUR
52W Low0.5300 EUR
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin-7657.96%
Oper. Margin-684.11%
ROE-30.82%
ROA-27.03%
Revenue Growth-12.20%
Earnings Growth—
Balance Sheet
Debt/Equity0.00
Current Ratio9.62
Quick Ratio9.55
Book Value/Sh0.4440 EUR
Cash/Share0.4080 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.277.23M
Float176.87M
Insiders34.96%
Institutions0.14%
Analyst Consensus
Rating—
Target (Mean)1.100 EUR
Target Range1.100 EUR – 1.100 EUR
# Analysts1
Company
Market Cap232.59M EUR
Enterprise Value119.99M EUR
Revenue (TTM)7.21M EUR
Gross Profit-26.69M EUR
Net Income (TTM)-37.52M EUR
Revenue/Share0.0500 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees145
Last Price0.8420 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0005175080